In Switzerland, consenting patients with moderate-to-severe psoriasis enter the SDNTT (Swiss Dermatology Network for Targeted Therapies) Psoriasis Registry when they start systemic treatment. The purpose of adding the outpatient data to the non-interventional registry lies in obtaining long-term evidence for the efficacy and safety of these therapies in psoriasis and comparing adverse and serious adverse events between biological and non-biological drugs.
In the evaluation presented, 473 patients were included until December 2016: this corresponds to 264 patient years of biological and 272 years of non-biological systemic therapy . Their mean age was 46.7 years, 65% were male and more than a third not only suffered from psoriasis but also from psoriatic arthritis.
Rates of serious adverse events and non-serious infection rates were not significantly different between the two treatment groups. The most reported non-serious adverse events were ineffectiveness of th...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Living in the golden age of psoriasis and atopic dermatitis therapies Next Article
New standard of care in extensive-stage small-cell lung cancer »
Table of Contents: AAD 2018
Psoriasis: an update
What's hot in atopic dermatitis
Pearls of the posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.